EMAIL THIS PAGE TO A FRIEND

Clinical transplantation

Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.


PMID 25739833

Abstract

Outcome of patients with transplant glomerulopathy (TG) is poor. Using B-cell targeting molecules represent a rational strategy to treat TG during chronic antibody-mediated rejection. In this pilot study, 21 patients with this diagnosis received four doses of intravenous immunoglobulins and two doses of rituximab (IVIG/RTX group). They were retrospectively compared with a untreated control group of 10 patients. At 24 months post-biopsy, graft survival was similar and poor between the treated and the untreated group, 47% vs. 40%, respectively, p = 0.69. This absence of response of IVIG/RTX treatment was observed, regardless the phenotype of TG. Baseline estimated glomerular filtration rate (eGFR) and decline in eGFR during the first six months after the treatment were risk factors associated with 24-month graft survival. The IVIG/RTX therapy had a modest effect on the kinetics of donor-specific alloantibodies at M24, compared to the untreated group, not associated with an improvement in graft survival. The mean number of adverse events per patient was higher in the IVIG/RTX group than in the control group (p = 0.03). Taken together, IVIG/RTX treatment for severe TG during chronic antibody-mediated rejection does not seem to change the natural history of TG and is associated with a high incidence of adverse events.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

HPA003563
Anti-C3 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA020432
Anti-C3 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
GW20073F Anti-Complement C3 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB1400110
Anti-GCNT2 antibody produced in mouse, IgG fraction of antiserum, buffered aqueous solution
HPA026776
Anti-GCNT2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1410519
Anti-GCNT2 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1407025
Anti-ST6GALNAC2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
AV53653
Anti-ST6GALNAC2 antibody produced in rabbit, affinity isolated antibody
SAB2701389
Anti-ST6GALNAC2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA048849
Anti-ST6GALNAC2 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA031734
Anti-TAF8 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2106983
Anti-TAF8 antibody produced in rabbit, affinity isolated antibody
SAB1410223
Anti-TAF8 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1408305
Anti-TBN antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB2106801
Anti-TCN2 antibody produced in rabbit, affinity isolated antibody
SAB1406586
Anti-VIPR1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA026777
Anti-VIPR1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4503084
Anti-VIPR1, C-Terminal antibody produced in rabbit, affinity isolated antibody
WH0000718M1
Monoclonal Anti-C3 antibody produced in mouse, clone 5F9, purified immunoglobulin, buffered aqueous solution
SAB1403622
Monoclonal Anti-C3 antibody produced in mouse, clone 5F9, ascites fluid
SAB1402938
Monoclonal Anti-TCN2 antibody produced in mouse, clone 2F4, purified immunoglobulin, buffered aqueous solution